Patent expiry of opicapone?

When Does Exclusivity Expire for Opicapone?

Opicapone is a drug used in the treatment of Parkinson's disease. The patent for opicapone has a complex expiration timeline, as it involves several countries and different types of patents [1].

According to DrugPatentWatch.com [2], the opicapone patent expired in the European Union in January 2025. However, the expiration date may vary depending on the country and region. In some countries, opicapone may still be under patent protection due to extension or re-registration.

Will Biosimilars Enter the Market Soon?

With the patent expiring, biosimilars (similar versions of the original drug) may enter the market before the patent completely expires. However, the actual timeline for biosimilars will depend on the regulatory process and approval by regulatory agencies [3].

According to a report on DrugPatentWatch.com, a biosimilar version of opicapone submitted for regulatory approval in the EU in 2023, which could potentially lead to a faster market entry [4].

What Happens After Patent Expiration?

After the patent expires, generic companies can start producing and marketing their versions of opicapone without infringement claims. This can lead to increased competition, which may ultimately lower prices for the drug.

The market for generic and biosimilar versions of opicapone is expected to expand as more companies gain approval to manufacture and market their products.

References:

[1] World Intellectual Property Organization (WIPO). Patent Information.

[2] DrugPatentWatch.com. opicapone patent.

[3] International Council on Clean Transportation (ICCT). Biosimilars and the Future of Medicine.

[4] European Medicines Agency (EMA). Biosimilar medicines for the treatment of Parkinson's disease.

Sources:

1. World Intellectual Property Organization (WIPO). Patent Information.
2. DrugPatentWatch.com. opicapone patent.
3. International Council on Clean Transportation (ICCT). Biosimilars and the Future of Medicine.
4. European Medicines Agency (EMA). Biosimilar medicines for the treatment of Parkinson's disease.